Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 19

1.
2.

Review article: management of patients with chronic hepatitis C virus infection and "normal" alanine aminotransferase activity.

Zeuzem S, Alberti A, Rosenberg W, Marcellin P, Diago M, Negro F, Prati D, Puoti C, Roberts SK, Shiffman ML.

Aliment Pharmacol Ther. 2006 Oct 15;24(8):1133-49. Review.

3.

[Hepatitis C virus infection--after 12 years. Advances in the management of chronic hepatitis C].

Pár A.

Orv Hetil. 2002 Dec 1;143(48):2667-74. Review. Hungarian.

PMID:
12501575
4.

[New trend in treatment in patients with chronic hepatitis C].

Werling K, Tulassay Z.

Orv Hetil. 2006 Apr 9;147(14):637-41. Review. Hungarian.

PMID:
16711370
5.

Patients with HCV and F1 and F2 fibrosis stage: treat now or wait?

Shiffman ML, Benhamou Y.

Liver Int. 2013 Feb;33 Suppl 1:105-10. doi: 10.1111/liv.12066. Review.

PMID:
23286853
6.

2011 European Association of the Study of the Liver hepatitis C virus clinical practice guidelines.

European Association of the Study of the Liver.

Liver Int. 2012 Feb;32 Suppl 1:2-8. doi: 10.1111/j.1478-3231.2011.02703.x. Review.

PMID:
22212565
7.

Antiviral treatment of HCV carriers with persistently normal ALT levels.

Puoti C, Bellis L, Galossi A, Guarisco R, Nicodemo S, Spilabotti L, Unto OD.

Mini Rev Med Chem. 2008 Feb;8(2):150-2. Review.

PMID:
18289098
8.

Advances in the treatment of hepatitis C.

Lawrence SP.

Adv Intern Med. 2000;45:65-105. Review.

PMID:
10635046
9.

Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.

Shepherd J, Brodin H, Cave C, Waugh N, Price A, Gabbay J.

Health Technol Assess. 2004 Oct;8(39):iii-iv, 1-125. Review.

10.

Treatment of patients with hepatitis C and normal serum aminotransferase levels.

Bacon BR.

Hepatology. 2002 Nov;36(5 Suppl 1):S179-84. Review.

PMID:
12407592
11.

Ranking predictors of a sustained viral response for patients with chronic hepatitis C treated with pegylated interferon and ribavirin in Scotland.

Innes HA, Hutchinson SJ, Allen S, Bhattacharyya D, Bramley P, Carman B, Delahooke TE, Dillon JF, Goldberg DJ, Kennedy N, Mills PR, Morris J, Morris J, Robertson C, Stanley AJ, Hayes P; Hepatitis C Clinical Database Monitoring Committee.

Eur J Gastroenterol Hepatol. 2012 Jun;24(6):646-55. doi: 10.1097/MEG.0b013e32835201a4. Review.

PMID:
22433796
12.

Treatment of chronic hepatitis C in southern Taiwan.

Chuang WL, Yu ML, Dai CY, Chang WY.

Intervirology. 2006;49(1-2):99-106. Review.

PMID:
16166797
13.

Interferon alpha (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluation.

Shepherd J, Jones J, Hartwell D, Davidson P, Price A, Waugh N.

Health Technol Assess. 2007 Mar;11(11):1-205, iii. Review.

14.

Natural history of hepatitis C and the impact of anti-viral therapy.

Boyer N, Marcellin P.

Forum (Genova). 2000 Jan-Mar;10(1):4-18. Review.

PMID:
10717254
15.

Treatment of chronic hepatitis C in Asia: when East meets West.

Yu ML, Chuang WL.

J Gastroenterol Hepatol. 2009 Mar;24(3):336-45. doi: 10.1111/j.1440-1746.2009.05789.x. Review.

PMID:
19335784
16.

Spotlight on peginterferon-alpha-2a (40 kD) plus ribavirin in the management of chronic hepatitis C mono-infection.

Keam SJ, Cvetković RS.

BioDrugs. 2009;23(1):63-8. doi: 10.2165/00063030-200923010-00007. Review.

PMID:
19344193
17.

Does antiviral therapy reduce the risk of hepatocellular carcinoma in patients with chronic hepatitis C?

Michielsen P, Ho E, Francque S.

Minerva Gastroenterol Dietol. 2012 Mar;58(1):65-79. Review.

PMID:
22419005
18.

Should patients with chronic hepatitis C who have normal ALT levels be treated?

Russo MW, Brown RS Jr.

Curr Gastroenterol Rep. 2001 Feb;3(1):49-53. Review.

PMID:
11177694
19.

Chronic hepatitis E infection: risks and controls.

Parvez MK.

Intervirology. 2013;56(4):213-6. doi: 10.1159/000349888. Epub 2013 May 9. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk